Antimicrobial Resistance (AMR) is one of the most urgent health challenges facing the world today as highlighted by WHO. It occurs when microorganisms such as bacteria, viruses, fungi, and parasites evolve to resist the effects of medications designed to kill or suppress them. This makes common infections harder to treat, leading to prolonged illness, disability, and increased risk of death. The misuse and overuse of antimicrobials, particularly antibiotics, are primary drivers of AMR, but other factors like inadequate infection prevention and control measures, and the lack of new antimicrobial development also play significant roles.
Antimicrobial Resistance: A Global Health Threat
Antimicrobials, including antibiotics, antivirals, antifungals, and antiparasitics, play an essential role in combating infectious diseases. They are critical tools in modern medicine, enabling surgeries, chemotherapy, and other life-saving medical procedures. However, the widespread use and misuse of these medicines, particularly antibiotics, have led to an increase in resistant pathogens, rendering many treatments ineffective.
Antimicrobial resistance occurs when bacteria, viruses, fungi, or parasites evolve to resist the effects of medicines that were once effective in treating infections. This resistance develops naturally over time, but the inappropriate use of antimicrobials—such as taking antibiotics for viral infections, not completing prescribed courses, and using substandard or counterfeit drugs—speeds up the process. Additionally, the overuse of antimicrobials in agriculture, particularly in animal farming, contributes to the spread of resistant organisms in both animals and humans.
Antimicrobial Resistance leads to longer hospital stays, higher medical costs, and increased mortality. The WHO has warned that if current trends continue, common infections and minor injuries could become life-threatening once again due to the lack of effective treatments. The rise of “superbugs,” which are resistant to multiple types of antimicrobials, has made this a critical global health emergency.
https://www.who.int/health-topics/antimicrobial-resistance
Inequitable Access to Antimicrobials
While overuse is a significant driver of AMR, many parts of the world still suffer from limited access to essential antimicrobial medicines. In low- and middle-income countries, millions of people die each year from infections that could have been treated if the right medicines were available. This lack of access is often due to weak health systems, insufficient supply chains, and high costs, leaving vulnerable populations without the treatments they need.
The disparity in access not only leads to unnecessary deaths but also worsens the AMR problem. When people in resource-limited settings cannot access the right antibiotics or other antimicrobials, they may turn to informal markets where medicines are often substandard, counterfeit, or misused. In such cases, even if patients have access to antimicrobials, they may receive inappropriate or ineffective treatment, further accelerating the development of resistance.
WHO’s Response and Global Action Plans
To combat AMR, the WHO has developed a global action plan, focusing on several key strategies. First, it emphasizes the importance of improving awareness and understanding of AMR through effective communication, education, and training. Public health campaigns and education initiatives are critical to informing both healthcare providers and the public about the risks of misuse and overuse of antimicrobials.
Second, WHO advocates for strengthening surveillance and research on AMR. Better data collection is essential to understanding the scope of the problem and guiding interventions. Improved diagnostic tools are also needed to ensure that antimicrobials are only prescribed when necessary.
Third, the WHO stresses the importance of optimising the use of antimicrobial medicines. This includes ensuring that healthcare systems have strong stewardship programs to manage the appropriate use of these drugs. Additionally, reducing the use of antimicrobials in agriculture is essential, as misuse in this sector also contributes to the spread of resistance.
Fourth, WHO calls for sustained investments in research and development to create new antimicrobials, vaccines, and diagnostic tools. Given that resistance is inevitable over time, the pipeline for new treatments must remain active to stay ahead of emerging threats.
Lastly, WHO emphasises the need for ensuring equitable access to existing and new antimicrobial medicines. This includes improving global supply chains, reducing the cost of these medicines, and strengthening health systems in low- and middle-income countries to provide timely and effective treatments to those in need.
Join Tishha
